NPPB and heart failure: B‐type natriuretic peptide, produced by the myocardium primarily in response to volume overload and increase in wall stress, and its inactive metabolite N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), are established prognostic markers in patients with heart failure and reduced ejection fraction (HFrEF).1 Similarly, elevated levels of cardiac troponins reflecting cardiomyocyte necrosis, consistently relate to worse clinical outcomes in both acute2, 3 and chronic4, 5, 6, 7, 8 HFrEF patients.